After Several FDA Setbacks, Idenix To Begin Clinical Study Of New HCV Nuc Outside The U.S.
This article was originally published in Pharmaceutical Approvals Monthly
Idenix plans to bypass FDA’s IND process and initiate Phase I/II testing of IDX21437 in Canada and Belgium. It hopes those data will lead to combination testing of the nucleoside polymerase inhibitor with IDX719, its NS5A inhibitor, by 2014.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.